English
norskBlar i forfatter "Bråthen, Geir"
Viser treff 1-12 av 12
-
Association of Klotho protein levels and KL-VS heterozygosity with Alzheimer disease and amyloid and tau burden
(Journal article; Tidsskriftartikkel; Peer reviewed, 2022-11-22)Importance Identification of proteins and genetic factors that reduce Alzheimer disease (AD) pathology is of importance when searching for novel AD treatments. Heterozygosity of the KL-VS haplotype has been associated with reduced amyloid and tau burden. Whether this association is mediated by the Klotho protein remains unclear. Objectives To assess concentrations of Klotho in cerebrospinal ... -
Cerebrospinal fluid neurogranin/β-site APP-cleaving enzyme 1 predicts cognitive decline in preclinical Alzheimer's disease
(Journal article; Tidsskriftartikkel; Peer reviewed, 2018-11-10)<i>Introduction</i>: The cerebrospinal fluid neurogranin (Ng)/β-site amyloid precursor protein-cleaving enzyme 1 (BACE1) ratio may reflect synaptic affection resulting from reduced beta-amyloid (Aβ) clearance. We hypothesize that increased Ng/BACE1 ratio predicts the earliest cognitive decline in Alzheimer’s disease.<p> <p><i>Methods</i>: We compared Ng/BACE1 levels between cases with subjective ... -
Genome-wide meta-analysis identifies new loci and functional pathways influencing Alzheimer's disease risk
(Journal article; Tidsskriftartikkel; Peer reviewed, 2019-01-07)Alzheimer’s disease (AD) is highly heritable and recent studies have identified over 20 disease-associated genomic loci. Yet these only explain a small proportion of the genetic variance, indicating that undiscovered loci remain. Here, we performed a large genome-wide association study of clinically diagnosed AD and AD-by-proxy (71,880 cases, 383,378 controls). AD-by-proxy, based on parental diagnoses, ... -
In Brief Neuropsychological Assessment, Amnestic Mild Cognitive Impairment (MCI) Is associated with Cerebrospinal Fluid Biomarkers for Cognitive Decline in Contrast to the Prevailing NIA-AA MCI Criterion
(Journal article; Tidsskriftartikkel; Peer reviewed, 2019-01-22)<i>Background:</i> In the care of persons with cognitive problems, it is important to use a valid mild cognitive impairment (MCI) criterion that discriminates well between normal and pathological aging.<p> <p><i>Objective:</i> To find the brief neuropsychological screening criterion that best correlates with cerebrospinal fluid (CSF) biomarkers for cognitive decline and dementia in persons ... -
Late onset myasthenia gravis is associated with HLA DRB1*15:01 in the Norwegian population
(Journal article; Tidsskriftartikkel; Peer reviewed, 2012)Acquired myasthenia gravis (MG) is a rare antibody-mediated autoimmune disease caused by impaired neuromuscular transmission, leading to abnormal muscle fatigability. The aetiology is complex, including genetic risk factors of the human leukocyte antigen (HLA) complex and unknown environmental factors. Although associations between the HLA complex and MG are well established, not all involved ... -
Longitudinal cerebrospinal fluid measurements show glial hypo- and hyperactivation in predementia Alzheimer’s disease
(Journal article; Tidsskriftartikkel; Peer reviewed, 2023-12-13)Background - Brain innate immune activation is associated with Alzheimer’s disease (AD), but degrees of activation may vary between disease stages. Thus, brain innate immune activation must be assessed in longitudinal clinical studies that include biomarker negative healthy controls and cases with established AD pathology. Here, we employ longitudinally sampled cerebrospinal fluid (CSF) core AD, ... -
Meta-analysis of Alzheimer’s disease on 9,751 samples from Norway and IGAP study identifies four risk loci
(Journal article; Tidsskriftartikkel; Peer reviewed, 2018-12-27)A large fraction of genetic risk factors for Alzheimer’s Disease (AD) is still not identified, limiting the understanding of AD pathology and study of therapeutic targets. We conducted a genome-wide association study (GWAS) of AD cases and controls of European descent from the multi-center DemGene network across Norway and two independent European cohorts. In a two-stage process, we first performed ... -
Predictive and diagnostic utility of brief neuropsychological assessment in detecting Alzheimer's pathology and progression to dementia
(Journal article; Tidsskriftartikkel; Peer reviewed, 2020)Objective: To assess the role of brief neuropsychological assessments in prediction and identification of Alzheimer’s disease (AD) pathology and progression to AD dementia. Method: Adults (N = 255; range = 40–81 years) with self-reported cognitive decline underwent baseline and 2-year follow-up clinical assessment, including a brief neuropsychological screening and lumbar puncture. Five different ... -
Regression-based norms for the FAS phonemic fluency test for ages 40–84 based on a Norwegian sample
(Journal article; Tidsskriftartikkel; Peer reviewed, 2021-05-08)<p>The FAS phonemic fluency test is a commonly used neuropsychological test of executive function and processing speed. Although Norwegian discrete norms have been developed for the FAS test, American regression-based norms are frequently used by clinicians in Norway. <p>However, language and cultural differences impact performance on the FAS test, and using foreign norms may not be appropriate. ... -
Regression-based norms for the FAS phonemic fluency test for ages 40–84 based on a Norwegian sample
(Mastergradsoppgave; Master thesis, 2023-01-06)The FAS phonemic fluency test is a commonly used neuropsychological test of executive function and processing speed. Although Norwegian discrete norms have been developed for the FAS test, American regression-based norms are frequently used by clinicians in Norway. However, language and cultural differences impact performance on the FAS test, and using foreign norms may not be appropriate. Moreover, ... -
Screening for Alzheimer’s Disease: Cognitive Impairment in Self-Referred and Memory Clinic-Referred Patients
(Journal article; Tidsskriftartikkel; Peer reviewed, 2017-11-07)<p>Background</i>: Cognitive assessment is essential in tracking disease progression in AD. Presently, cohorts including preclinical at-risk participants are recruited by different means, which may bias cognitive and clinical features. We compared recruitment strategies to levels of cognitive functioning.<p> <p><i>Objective</i>: We investigate recruitment source biases in self-referred and ... -
Stable cerebrospinal fluid neurogranin and β-site amyloid precursor protein cleaving enzyme 1 levels differentiate predementia Alzheimer's disease patients
(Journal article; Tidsskriftartikkel; Peer reviewed, 2022-09-24)Cerebrospinal fluid (CSF) β-site amyloid precursor protein cleaving enzyme 1 (BACE1), neurogranin and the neurogranin/BACE1 ratio are proposed markers for Alzheimer’s disease. BACE1 is also a drug target. However, CSF levels may differ between early-stage amyloid plaque formation (A) and later stage downstream tau-tangle pathology (T) and neurodegeneration (N) and may be expressed as an A/T/N stage ...
